Financial Performance - Net profit attributable to shareholders rose by 66.25% to CNY 168,530,398.04 for Q1 2025, up from CNY 101,369,815.90 in Q1 2024[9] - Operating revenue for Q1 2025 reached CNY 366,465,963.91, marking a 62.51% increase from CNY 225,500,687.12 in the same period last year[9] - The company's net asset return rate based on net profit attributable to shareholders was 10.41% for Q1 2025, compared to 10.09% in Q1 2024[9] - Net profit for Q1 2025 was CNY 168,180,946.38, compared to CNY 101,368,431.82 in Q1 2024, reflecting a growth of approximately 65.9%[34] - The company reported a total comprehensive income of ¥172,319,351.25 for Q1 2025, compared to ¥104,328,856.62 in Q1 2024, indicating a growth of approximately 65.3%[36] Asset and Liability Management - Total assets increased by 9.89% to CNY 2,259,361,999.79 as of March 31, 2025, compared to CNY 2,056,073,416.98 at the end of 2024[9] - The total liabilities to assets ratio decreased to 24.74% from 25.53% year-on-year, reflecting a stronger balance sheet[9] - The total liabilities rose from CNY 524,865,480.46 to CNY 558,973,116.89, indicating an increase of about 6.49%[29] - The total equity attributable to shareholders increased from CNY 1,535,213,828.42 to CNY 1,703,744,226.46, reflecting a growth of approximately 10.96%[29] - The total assets as of March 31, 2025, amounted to CNY 2,319,351,534.88, an increase from CNY 2,130,232,409.16 as of December 31, 2024[32] Cash Flow and Investments - The company’s cash flow from operating activities increased by 66.11% to CNY 174,223,451.19, compared to CNY 104,883,073.28 in Q1 2024[9] - Cash and cash equivalents amounted to CNY 958,678,503.23, up from CNY 941,124,763.40, showing an increase of about 1.6%[27] - The cash inflow from investment activities in Q1 2025 was ¥441,024,969.32, significantly higher than ¥100,216,232.88 in Q1 2024, reflecting a growth of about 340.0%[39] - The company incurred a net cash outflow from investment activities of ¥148,610,115.12 in Q1 2025, compared to a net outflow of ¥32,989,212.49 in Q1 2024[39] - The net increase in cash and cash equivalents was 54,156,246.96, representing a decrease of about 74.1%[41] Research and Development - Research and development expenses surged by 85.24% to CNY 19,030,382.10, reflecting a focus on the development of recombinant human collagen products[12] - Research and development expenses for Q1 2025 were CNY 19,030,382.10, compared to CNY 10,273,125.12 in Q1 2024, indicating an increase of approximately 85.5%[33] - Research and development expenses for Q1 2025 were ¥19,026,922.10, compared to ¥10,139,363.12 in Q1 2024, showing an increase of about 87.5%[35] Shareholder Information - The total number of ordinary shares is 88,511,800, with 51.85% being unrestricted shares[16] - Major shareholder Yang Xia holds 58.89% of the shares, totaling 52,128,440 shares[17] - The company has 4,675 ordinary shareholders as of the end of the reporting period[16] - The total number of restricted shares is 42,620,720, representing 48.15% of the total shares[16] Legal and Regulatory Matters - There were no significant legal disputes or arbitration matters reported during the period[21] - The company has not engaged in any significant asset acquisitions or disposals during the reporting period[21] Other Financial Metrics - The gross profit margin for the period improved significantly, with operating costs rising by 98.30% to CNY 36,235,023.96 due to increased sales[12] - Non-recurring gains and losses totaled CNY 1,630,272.44, with a net amount of CNY 1,387,158.35 after tax effects[14] - The company reported a loss of CNY 221,464.12 from the disposal of non-current assets[13] - Government subsidies recognized in the current period amounted to CNY 2,065,347.84, closely related to the company's normal operations[13]
锦波生物(832982) - 2025 Q1 - 季度财报